<DOC>
	<DOC>NCT02576639</DOC>
	<brief_summary>The study will determine the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling will be obtained in order to define the target dose in subsequent efficacy studies.</brief_summary>
	<brief_title>Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Key Healthy status Body weight: ≥45kg BMI: 1834 kg/m2 Key History or presence of any clinically significant disease of any major system organ class. Heavy smoker status History /presence of clinically significant neurological or psychiatric disorders Any medical condition that might lead to or is associated with any cognitive deficit History or presence of severely impaired renal function</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Alzheimer's Disease,</keyword>
	<keyword>Amyloid Beta,</keyword>
	<keyword>cerebrospinal fluid,</keyword>
	<keyword>beta secretase</keyword>
</DOC>